Emily Plautz, PA
Physician Assistant · Lincoln, NENPI 1215352505
Payments from drug & device makers
Across 168 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascensia Diabetes Care US Inc.$326
- Lilly USA, LLC$280
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$259
- Novo Nordisk$184
- AstraZeneca$175
- Abbott$130
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,441100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascensia Diabetes Care US Inc. | 22 | $326 |
| Lilly USA, LLC | 20 | $280 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 37 | $259 |
| Novo Nordisk | 12 | $184 |
| AstraZeneca | 5 | $175 |
| Abbott | 7 | $130 |
| Amgen(2 entities) | 7 | $117 |
| Medtronic | 5 | $96 |
| Tandem Diabetes Care, Inc. | 6 | $94 |
| Zealand Pharma US, Inc. | 6 | $94 |
| Sanofi-aventis U.S. LLC | 6 | $84 |
| Xeris Pharmaceuticals, Inc. | 3 | $74 |
| Corcept Therapeutics | 3 | $65 |
| Recordati_rare_diseases_inc. | 3 | $57 |
| Boehringer Ingelheim | 3 | $53 |
| Antares Pharma, Inc. | 2 | $40 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Mannkind Corporation | 2 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
| Amryt Pharma Holdings Ltd | 2 | $25 |
| Nevro Corp. | 1 | $22 |
| Halozyme Inc | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| BETA Bionics, Inc. | 1 | $16 |
| Cequr Corporation | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$115
How this compares
$2,453 in reported general payments places this provider in the 85th percentile of 1,127 physician assistant providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 199 | $256,365 |
| MounjaroTirzepatide | 187 | $200,463 |
| TrulicityDulaglutide | 114 | $147,615 |
| Humalog Kwikpen U-200Insulin Lispro | 75 | $143,026 |
| Tresiba Flextouch U-200Insulin Degludec | 107 | $130,008 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 79 | $101,207 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $93,293 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 77 | $77,140 |
| FarxigaDapagliflozin Propanediol | 71 | $66,544 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 24 | $51,146 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 41 | $47,218 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 16 | $39,184 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $31,562 |
| JardianceEmpagliflozin | 33 | $30,196 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $23,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $280 | $363,990347 claims |
| Novo NordiskOzempic, Novolog | $184 | $266,021223 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $84 | $77,14077 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Jentadueto Xr | $53 | $70,21573 claims |
| AstraZenecaFarxiga | $175 | $66,54471 claims |
| AbbVieSynthroid | $14 | $16,613136 claims |
| IBSA Pharma Inc.Tirosint | $15 | $8,35518 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $3,614370 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,127 physician assistant providers in Nebraska.
Other physician assistant in Lincoln
- Laura TvrdyLincoln$13K
- Courtney MaresLincoln$13K
- Jacklynn KmentLincoln$10K
- Bethany LambertLincoln$9K
- Kelsey WerginLincoln$8K
- Makayla DoolittleLincoln$7K
- Christina MeyerLincoln$7K
- Ashley JohnsonLincoln$7K
- Shaun RingLincoln$7K
- Katelyn EspinozaLincoln$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.